Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Global Market Opportunities and Strategies to 2035

This report describes and explains the EPI therapeutics and diagnostics market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global EPI therapeutics and diagnostics market reached a value of nearly $6.11 billion in 2025, having grown at a compound annual growth rate (CAGR) of 7.5% since 2020. The market is expected to grow from $6.11 billion in 2025 to $8.62 billion in 2030 at a rate of 7.1%. The market is then expected to grow at a CAGR of 6.5% from 2030 and reach $11.83 billion in 2035.

Growth in the historic period resulted from rising demand for personalized medicine, expansion of healthcare infrastructure, improved clinical awareness and screening programs and rising prevalence of gastrointestinal disorders. Factors that negatively affected growth in the historic period were high cost of long-term management and limited insurance coverage for diagnostic procedures.

Going forward, Government Initiatives For research and development in healthcare, rising global prevalence of pancreatic disorders, rise in aging population and increasing prevalence of diabetes will drive the growth. Factors that could hinder the growth of the EPI therapeutics and diagnostics market in the future include high underdiagnosis and misdiagnosis rates, side effects of enzyme therapy and impact of trade war and tariff.

Market trends for the EPI therapeutics and diagnostics market include enhanced affordability programs supporting commercially insured EPI patients, advancements in next-generation pancreatic enzyme replacement therapies (PERT) and strategic collaboration accelerates non-porcine enzyme innovation in EPI.

The EPI therapeutics and diagnostics market is segmented by type into therapies and diagnostics. The therapies market was the largest segment of the EPI therapeutics and diagnostics market segmented by type, accounting for 74.8% or $4.57 billion of the total in 2025. Going forward, the diagnostics segment is expected to be the fastest growing segment in the EPI therapeutics and diagnostics market segmented by type, at a CAGR of 7.8% during 2025-2030.

The EPI therapeutics and diagnostics market is segmented by distribution channel into direct tender, retail pharmacy, third-party distributor, and other distribution channels. The direct tender market was the largest segment of the EPI therapeutics and diagnostics market segmented by distribution channel, accounting for 50.1% or $3.06 billion of the total in 2025. Going forward, the other distribution channels segment is expected to be the fastest growing segment in the EPI therapeutics and diagnostics market segmented by distribution channel, at a CAGR of 9.7% during 2025-2030.

The EPI therapeutics and diagnostics market is segmented by end user into hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, and other end users. The hospitals market was the largest segment of the EPI therapeutics and diagnostics market segmented by end user, accounting for 28.7% or $1.75 billion of the total in 2025. Going forward, the homecare segment is expected to be the fastest growing segment in the EPI therapeutics and diagnostics market segmented by end user, at a CAGR of 8.5% during 2025-2030.

North America was the largest region in the EPI therapeutics and diagnostics market, accounting for 40.8% or $2.49 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the EPI therapeutics and diagnostics market will be Asia Pacific and Western Europe where growth will be at CAGRs of 9.3% and 6.6% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 6.3% and 6.1% respectively.

The global EPI therapeutics and diagnostics market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 58.82% of the total market in 2024. Amazon.com Inc. (AWS) was the largest competitor with a 24.17% share of the market, followed by Nestle Health Science SA (Zenpep) with 15.23%, Abbott Laboratories with 13.62%, Nordmark Arzneimittel GmbH & Co. KG, with 2.12%, DiaSorin S.p.A., with 0.90%, Organon group of companies (COTAZYM) with 0.80%, Vivus Inc. with 0.75%, Quest Diagnostics Incorporated with 0.67%, Genova Diagnostics with 0.29% and Alcresta Therapeutics Inc. with 0.27%.

The top opportunities in the EPI therapeutics and diagnostics market segmented by type will arise in the therapies segment, which will gain $1.81 billion of global annual sales by 2030. The top opportunities in the EPI therapeutics and diagnostics market segmented by distribution channel will arise in the direct tender segment, which will gain $1.07 billion of global annual sales by 2030. The top opportunities in the EPI therapeutics and diagnostics market segmented by end user will arise in the specialty clinics segment, which will gain $771.7 million of global annual sales by 2030. The EPI therapeutics and diagnostics market size will gain the most in the USA at $787 million.

Player-adopted strategies in the EPI therapeutics and diagnostics market include focuses on expanding its business capabilities through strategic partnerships and business expertise.

Market-trend-based strategies for the EPI therapeutics and diagnostics market include focusing on the Patient Cost-Sharing Relief Program rolled out for pancreatic enzyme replacement therapy, next-generation PERT formulation designed for optimized intestinal delivery and investigational lipase therapy, securing development and commercialization partners. Developing a novel pancreatic enzyme replacement therapy (PERT) requires substantial investment in research.

To take advantage of the opportunities, the analyst recommends the EPI therapeutics and diagnostics companies to focus on expanding patient cost relief programs to improve adherence and outcomes, focus on advancing next-generation pert formulations for improved delivery and compliance, focus on expanding diagnostics segment for high-growth opportunities, expand in emerging markets, continue to focus on developed markets, focus on expanding multi-channel distribution for epi therapeutics and diagnostics, focus on strategic partnerships to accelerate novel lipase therapy development, focus on value based tiered pricing and access alignment, focus on targeted disease awareness and early diagnosis, focus on data-driven multichannel engagement and stakeholder alignment, focus on expanding homecare segment for sustained growth, focus on scaling digital and alternative distribution channels.

This product will be delivered within 3-5 business days.